Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trialHIV의 2차 치료를 위한 로피나비르 + 뉴클레오시드 역전사효소 억제제, 로피나비르 + 랄테그라비르 또는 로피나비르 단독요법(EARNEST): 무작위 대조 시험의 144주 추적 결과Article Published on 2018-01-012022-09-06 Journal: The Lancet. Infectious Diseases [Category] Communicable Disease, [키워드] adverse event African AID analysed Analysis Antiretroviral therapy ART assigned best clinical Combination combination therapy completion computer-generated cooperation country criteria Developing development Efficacy eligibility European event finding FIVE Follow-up funding GRADE grade 3 group HIV-infected people inferiority inhibitor inhibitors intervention group ISRCTN Kenya less limit Lopinavir Medical Research Council Modification monotherapy no difference non-inferiority non-inferiority margin nucleoside offer offered outcome participant partnership Patient per day primary analysis Primary outcome protease Protease inhibitor raltegravir randomisation randomised controlled trial Randomly receive recent regimen regimens Registered Ritonavir screened sequence Serious Adverse Events Swedish Treatment treatment of HIV Trial two-sided α Uganda Viral Viral load viral loads Virological WHO WHO criteria WHO guideline Zimbabwe [DOI] 10.1016/S1473-3099(17)30630-8 PMC 바로가기 [Article Type] Article
A review of candidate therapies for Middle East respiratory syndrome from a molecular perspectiveReview Published on 2017-09-302022-10-29 Journal: Journal of Medical Microbiology [Category] Coronavirus, MERS, [키워드] acute respiratory syndrome Antibiotics antiviral peptide camostat cathepsin L clinical trials Combination Controlled clinical trial convalescent convalescent plasma Corticosteroids current therapy DPP4 East effective furin protease GLS-5300 glycopeptide antibiotic high mortality rate host proteases include inhibitor interferon interferons laboratory-confirmed Lopinavir Lopinavir–ritonavir M(pro) Medline database MERS-CoV Middle East molecular monoclonal antibodies mortality rate Mutation pandemic Perspective PL(pro) potential therapy protease required respiratory syndrome coronavirus ribavirin S protein SARS-CoV searched subject syndrome Therapies therapy TMPRSS2 Transmissibility urgency Vaccine vaccine candidates Variation viral S protein [DOI] 10.1099/jmm.0.000565 PMC 바로가기 [Article Type] Review
Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial공중 보건 접근법에서 뉴클레오시드 역전사효소 억제제 교차 내성 및 2차 항레트로바이러스 요법의 결과: 무작위, 공개, EARNEST 시험 내 관찰 분석Articles Published on 2017-05-082022-09-06 Journal: The Lancet. HIV [Category] Communicable Disease, [키워드] AID Analysis Antiretroviral therapy ART assigned association baseline calculated clinical cooperation Cross-resistance Developing development European Evidence expected finding Follow-up funding Genotype genotypic greater impair inhibitor ISRCTN Lopinavir Medical Research Council monotherapy nucleoside Open-label outcome over partnership Patient patients with HIV predict predicted protease Protease inhibitor public health raltegravir randomised Randomised trial Randomly Registered Ritonavir sub-Saharan Africa Support Swedish tested therapy Treatment outcome Trial Viral Viral load Virological virological outcome virological outcomes WHO WHO criteria with HIV [DOI] 10.1016/S2352-3018(17)30065-6 PMC 바로가기 [Article Type] Articles
Treatment With Lopinavir/Ritonavir or Interferon-β1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common MarmosetArticle Published on 2015-12-152023-06-15 Journal: The Journal of Infectious Diseases [Category] MERS, [키워드] animal Common marmoset coronavirus interferon Kaletra Lopinavir MERS mycophenolate primate Treatment [DOI] 10.1093/infdis/jiv392 PMC 바로가기
Protease inhibitor monotherapy for long-term management of HIV infection: a randomised, controlled, open-label, non-inferiority trialHIV 감염의 장기 관리를 위한 프로테아제 억제제 단독 요법: 무작위, 대조, 공개, 비열등성 시험Articles Published on 2015-09-142022-09-06 Journal: The Lancet. HIV [Category] Communicable Disease, [키워드] 1:1 adverse event age Antiretroviral therapy ART baseline benefit block CD4 Cell Clinical management Clinical outcome clinical risk Combination combination treatment computer-generated Controlled darunavir defined drug drug resistance enrolled finding Frequency funding Genetic GRADE grade 3 HIV HIV infection inferiority inhibitor Intention intention to treat international standard Kaplan-Meier Kaplan-Meier analysis Lopinavir maintain management monotherapy non-inferiority non-inferiority margin non-inferiority trial number once daily Open-label parallel-group participant positive Pragmatic preserved Primary outcome Probability Protease inhibitor protease inhibitors public sector randomisation randomisation list randomised Randomly rebound Registered Ritonavir Serious Adverse Events shown Standard stratified suppressed the patient therapy toxic effects Treatment treatment failure Trial Viral Viral load virus [DOI] 10.1016/S2352-3018(15)00176-9 PMC 바로가기 [Article Type] Articles
Ritonavir-boosted indinavir but not lopinavir inhibits erythrocytic stage Plasmodium knowlesi malaria in rhesus macaquesArticle Published on 2015-04-012024-08-29 Journal: Bioorganic & Medicinal Chemistry Letters [Category] 말라리아, [키워드] Indinavir Lopinavir Plasmodium knowlesi rhesus macaques Ritonavir